Journal of Clinical Pharmacy and Therapeutics

Cover image for Vol. 41 Issue 2

Edited By: A. Li Wan Po

Impact Factor: 1.668

ISI Journal Citation Reports © Ranking: 2014: 171/255 (Pharmacology & Pharmacy)

Online ISSN: 1365-2710

Recently Published Issues

See all

Recently Published Articles

  1. Micafungin and a case of polymorphic ventricular tachycardia

    P. J. Shah, V. Sundareshan, B. Miller and S. J. Bergman

    Article first published online: 28 APR 2016 | DOI: 10.1111/jcpt.12386

    Thumbnail image of graphical abstract

    This patient developed polymorphic ventricular tachycardia suggestive of Torsades de pointes following the initiation of micafungin for esophageal candidiasis while on amiodarone. Based on the timing of this event, the Naranjo probability scale for adverse drug reactions indicates a possible association.

  2. You have full text access to this OnlineOpen article
    Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study

    T. Hosoya, T. Sasaki, H. Hashimoto, R. Sakamoto and T. Ohashi

    Article first published online: 15 APR 2016 | DOI: 10.1111/jcpt.12392

    Thumbnail image of graphical abstract

    We evaluated the dose–response relationship in respect of the serum urate-lowering efficacy of topiroxostat, a novel selective xanthine oxidoreductase inhibitor for the treatment of hyperuricemia with or without gout in Japan, which was newly developed by Fuji Yakuhin Co., Ltd. The study demonstrated its dose–response relationship in respect of the serum urate reduction and a superior mean per cent change of the serum urate from the baseline at the end of the study period.

  3. Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies

    F.-J. Wang, Y. Wang, T. Niu, W.-X. Lu, A. J. Sandford and J.-Q. He

    Article first published online: 9 APR 2016 | DOI: 10.1111/jcpt.12388

    Thumbnail image of graphical abstract

    We performed a large meta-analysis on the association of the CYP2E1 polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity (ATDH). The overall ORs of relevant studies demonstrated that the CYP2E1 RsaI/PstI C1/C1 genotype was associated with an elevated risk of ATDH (OR = 1.32, 95% CI 1.03–1.69, P = 0.027).